India’s Ozone Targets Five Half-Price Generics For Indian Market
This article was originally published in PharmAsia News
Ozone Group says it plans to bring to India's market in July five drugs it will price at half the cost of what already is available. Ozone is one of a group of Indian pharmas seeking to counter an influx of questionable branded drugs into India by offering cheaper generics. Ozone's plans are focused on five drugs - an antibiotic and drugs to treat diarrhea, ulcers, pyretic and a painkiller. The firm's chairman and managing director. S.C. Sehgal, said the intent is to make available cheaper drugs with no sacrifice of quality, so he does not expect to garner major revenues from the drugs. (Click here for more
You may also be interested in...
The UK's Advertising Standards Authority will closely monitor the marketing communications of dietary supplements e-tailer Health Solutions after it failed to provide a substantive response to health claims regulation breaches.
Consensus report CR511 from the Association for the Advancement of Medical Instrumentation highlights common system elements for engineers, and outlines safety and risk-control measures that manufacturers and caregivers should consider.
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.